Navigation Links
FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
Date:9/10/2010

WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.(1) The FDA approval of FASLODEX 500mg was based on results from CONFIRM (COmparisoN of FASLODEX In Recurrent or Metastatic breast cancer), a Phase III study which demonstrated that FASLODEX 500mg significantly reduced the risk of disease progression in patients with metastatic breast cancer, when compared with the 250mg dose. Safety and tolerability profiles of both doses were comparable.(2)

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO)

"This approval is an important advancement for women with metastatic breast cancer, where the treatment approach is centered on delaying disease progression," said Gershon Locker, M.D., Medical Director for AstraZeneca. "FASLODEX at 250mg has been an important treatment option for many women, and we now have data to show that the new 500mg dosing regimen can improve progression free survival compared with the 250mg dose."

The recommended dose of FASLODEX 500mg should be administered intramuscularly into the buttocks as two 250mg injections, one in each buttock, on days 1, 15, 29 and once monthly thereafter. A dose of 250mg is recommended in patients with moderate hepatic impairment.(1)

FASLODEX 500mg will be supplied as 2 x 250mg/5mL packaged together in early fourth qu
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Pediatric Use of Chemical Poisoning Treatment
2. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
3. FDA Approves Vaccines for the 2010-2011 Influenza Season
4. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
5. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
6. U.S. FDA Approves Improved Performance of Riverain Medicals OnGuard Chest X-ray Computer-Aided Detection Technology
7. FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
8. FDA Approves New Treatment for Late-Onset Pompe Disease
9. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
10. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
11. FDA Approves New Combination Product Oral Contraceptive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... York , January 14, 2014 ... System Transfer Devices (CSTD) for hazardous drugs, today announced that ... the fourth straight year.   Equashield,s ... pharmacy technicians, pharmacists, nurses and other medical professionals ...
(Date:1/14/2014)... Therapeutics , a late-stage gene therapy company, has reached its patient ... study for inherited retinal dystrophies caused by mutations in the ... presenting this and other corporate updates today, at the 32nd Annual ... Marrazzo said Spark was able to achieve its recruitment goal a ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... For the second consecutive year, the Exergen temporal artery ... stock the product, according to Nielsen and Information Resources ... including national brands and private label products, were compared. ... share has risen to 20 percent of all thermometers ...
... 2011 JLL Partners Inc. is pleased to announce ... PharmaNet Development Group, Inc. ("PharmaNet") to inVentiv Health, Inc. ... and inVentiv Health, Inc. is a leading global provider ... pharmaceutical and healthcare industries. Ramsey A. Frank, ...
Cached Medicine Technology:JLL Partners Sells PharmaNet 2
(Date:7/10/2014)... Reducing the amount of alcoholic beverages consumed, ... including a reduced risk of coronary heart disease, ... according to a new multi-center study published in ... Perelman School of Medicine at the University of ... studies which suggest that consuming light-to-moderate amounts of ...
(Date:7/10/2014)... students looking to bump up their grade point averages ... time in a library or study hall, but in ... that students who were members of the recreational sports ... and sophomore years had higher GPAs than those who ... with memberships stayed in school longer. An increase of ...
(Date:7/10/2014)... studies have shown that more severe illness and even ... secondary respiratory infection after developing influenza. Now, however, a ... determined that if you reverse the order of infection, ... may actually protect against a bad case of the ... protein pneumolysin, which is described as a bacterial virulence ...
(Date:7/10/2014)... cancer were more likely to be diagnosed with ... and survived for shorter times than prostate cancer ... has found. , The negative outcomes may be ... against the mentally ill, depression,s impact on biological ... in his general health and disinterest in receiving ...
(Date:7/10/2014)... who experience hot flashes are unlikely to talk much ... silent suffering if they are willing to try ... University case study., After seven weeks of hypnotic relaxation ... following prostate cancer surgery showed a drastic decrease not ... in sleep quality, according to the study., The Baylor ...
Breaking Medicine News(10 mins):Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:Want a higher GPA in college? Join a gym 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4
... June 18 Roxane Laboratories, Inc.,announced today ... Application (ANDA),for Ramipril Capsules, 1.25mg, 2.5mg, 5mg ... Administration. The 1.25mg, 2.5mg, 5mg and 10mg ... Roxane Laboratories Ramipril,Capsules are available for immediate ...
... cancer who had abundant vitamin D in their blood were ... who were deficient in the vitamin, according to a new ... of the study -- the first to examine the effect ... research, but it is too early to recommend supplements as ...
... a human patient,s cloned infection-fighting T cells as the sole ... A team led by Cassian Yee, M.D., an associate member ... Center, reports these findings in the June 19 issue of ... and colleagues removed CD4+ T cells, a type of white ...
... Authority continues monitoring and evaluating wrong-site surgeries,with ... wrong-site surgery,update, HARRISBURG, Pa., June 18 ... "National Time Out Day," which is a,national ... time out" before every,operation to confirm correct ...
... DENVER, June 18 Air Methods Corporation,(Nasdaq: ... in the,world, announced today that Chief Executive Officer ... present at the Jefferies 2nd Annual,Healthcare Conference in ... at 11:15,a.m. ET., Interested parties can listen ...
... in Indiana to propose awareness-raising ... legislation in 2009., ... of July as Indiana Safe Haven Month and the,National Safe Haven ... for babies who were adopted thanks to legislation,passed overwhelmingly in the ...
Cached Medicine News:Health News:Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules 2Health News:Study links vitamin D to colon cancer survival 2Health News:Patient's own infection-fighting T cells put late-stage melanoma into long-term remission 2Health News:Patient Safety Authority Supports 'National Time Out Day' 2Health News:Governor and Lt. Governor Celebrate Eight Years of Safe Haven Babies 2
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... The Low Profile Leg Holder provides precise control ... leg rotation, and maximum exposure of the proximal ... Profile Leg Holder can be used on both ... to different heights.,The Low Profile Leg Holder can ...
... knee during surgery. Slotted base allows the ... knee surgery. Slots are also designed to allow ... can be sterilized by either gas or steam ... can be clamped over the sterile drape to ...
... The True/Flex Upper Extremity Intramedullary Rod System ... alternative to conventional methods of rodding and ... micromotion at the fracture site and enhanced ... rods to be easily inserted into the ...
Medicine Products: